134 related articles for article (PubMed ID: 37357120)
21. Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach.
Fleischmann M; Diefenhardt M; Trommel M; Scherf C; Ramm U; Chatzikonstantinou G; Fokas E; Rödel C; Tselis N
Strahlenther Onkol; 2022 Jul; 198(7):654-662. PubMed ID: 35445815
[TBL] [Abstract][Full Text] [Related]
22. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
23. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
[TBL] [Abstract][Full Text] [Related]
24. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.
Frin AC; Evesque L; Gal J; Benezery K; François E; Gugenheim J; Benizri E; Château Y; Marcié S; Doyen J; Gérard JP
Eur J Cancer; 2017 Feb; 72():124-136. PubMed ID: 28027515
[TBL] [Abstract][Full Text] [Related]
25. Non-operative management involving chemoradiation therapy combined with high-dose-rate brachytherapy for T3 rectal cancer using a vaginal shielded cylindrical applicator: a technical report.
Murakami N; Kojima K; Okuma K; Kashihara T; Nakamura S; Shimizu W; Suda R; Igaki H; Shikama N
Jpn J Clin Oncol; 2023 Nov; 53(11):1082-1086. PubMed ID: 37554048
[TBL] [Abstract][Full Text] [Related]
26. Contact X-ray brachytherapy for rectal cancer: Past, present, and future.
Gérard JP; Barbet N; Dejean C; Montagne L; Bénézery K; Coquard R; Doyen J; Durand Labrunie J; Hannoun-Lévi JM
Cancer Radiother; 2021 Dec; 25(8):795-800. PubMed ID: 34052134
[TBL] [Abstract][Full Text] [Related]
27. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].
Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305
[No Abstract] [Full Text] [Related]
28. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
29. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
[No Abstract] [Full Text] [Related]
30. Chemoradiotherapy in gastrointestinal malignancies.
Willett CG; Czito BG
Clin Oncol (R Coll Radiol); 2009 Sep; 21(7):543-56. PubMed ID: 19577442
[TBL] [Abstract][Full Text] [Related]
31. Locally advanced rectal cancer: Preliminary results of rectal preservation after neoadjuvant chemoradiotherapy.
Vaccaro CA; Yazyi FJ; Ojra Quintana G; Santino JP; Sardi ME; Beder D; Tognelli J; Bonadeo F; Lastiri JM; Rossi GL
Cir Esp; 2016 May; 94(5):274-9. PubMed ID: 26980259
[TBL] [Abstract][Full Text] [Related]
32. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
33. Propensity score analysis of radical proctectomy versus organ preservation using contact X-ray brachytherapy for rectal cancer.
Gerard JP; Montagne L; Thamphya B; Doyen J; Schiappa R; Benezery K; Gourgou S; Dejean C; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Mar; 33():70-76. PubMed ID: 35118202
[TBL] [Abstract][Full Text] [Related]
34. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
[TBL] [Abstract][Full Text] [Related]
35. High-Dose-Rate Brachytherapy in the Management of Operable Rectal Cancer: A Systematic Review.
Buckley H; Wilson C; Ajithkumar T
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):111-127. PubMed ID: 28816137
[TBL] [Abstract][Full Text] [Related]
36. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy.
Wang QX; Zhang R; Xiao WW; Zhang S; Wei MB; Li YH; Chang H; Xie WH; Li LR; Ding PR; Chen G; Zeng ZF; Wang WH; Wan XB; Gao YH
Radiat Oncol; 2021 Jan; 16(1):16. PubMed ID: 33468176
[TBL] [Abstract][Full Text] [Related]
37. Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience.
Sun Myint A; Smith FM; Gollins S; Wong H; Rao C; Whitmarsh K; Sripadam R; Rooney P; Hershman M; Pritchard DM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):565-573. PubMed ID: 29229327
[TBL] [Abstract][Full Text] [Related]
38. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
39. [Rectal Cancer: Organ preservation and neoadjuvant treatment escalation].
Vendrely V; Rullier E
Bull Cancer; 2021 Dec; 108(12):1126-1131. PubMed ID: 34802716
[TBL] [Abstract][Full Text] [Related]
40. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
